"Né de la fusion de deux établissements de soins en 2010, l'Hôpital privé de l’Estuaire, établissement du groupe Ramsay Santé, au Havre, prend en charge chaque année près de 10 000 patients en hospitalisation complète (chirurgie et médecine) et 17 000 patients en chirurgie ambulatoire grâce à sa grande capacité d'accueil. Ses équipes allient leurs savoir-faire pour vous accueillir dans les meilleures conditions durant votre séjour."

During the past decade, Hôpital Privé de l'Estuaire conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Privé de l'Estuaire" #1 sponsor was "Intergroupe Francophone de Cancerologie Thoracique" with 2 trials, followed by "ARCAGY/ GINECO GROUP" with 1 trials sponsored, "Biotronik AG" with 1 trials sponsored, "Biotronik France" with 1 trials sponsored and "Centre Oscar Lambret" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Privé de l'Estuaire" #1 collaborator was "Agence Régional de Santé du Centre" with 1 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Biotronik France" with 1 trials as a collaborator and "Breast International Group" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Privé de l'Estuaire" are "ALK Gene Mutation" (1 trials), "Abdominal Aortic Aneurysm" (1 trials), "Angioplasty" (1 trials), "BRAF Gene Mutation" (1 trials) and "Breast Ductal Carcinoma In Situ" (1 trials). Many other conditions were trialed in "Hôpital Privé de l'Estuaire" in a lesser frequency.

Most popular intervention types in "Hôpital Privé de l'Estuaire" are "Drug" (3 trials), "Device" (2 trials), "Other" (2 trials), "Behavioral" (1 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Anastrozole" (1 trials), "Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)" (1 trials), "Atezolizumab" (1 trials), "Cyclophosphamide" (1 trials) and "Dose-dense Doxorubicin or dose-dense Epirubicin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Privé de l'Estuaire" are 10 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Hôpital Privé de l'Estuaire". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Hôpital Privé de l'Estuaire, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Privé de l'Estuaire, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".